NASDAQ:IOBT

IO Biotech (IOBT) Stock Forecast, Price & News

$2.00

-0.02 (-0.99%)

(As of 06/5/2023 ET)

Compare

Today's Range: $1.96
▼
$2.03
50-Day Range: $1.80
▼
$2.15
52-Week Range: $1.72
▼
$5.76

Volume: 7,374 shs
Average Volume: 52,448 shs
Market Capitalization: $57.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

IO Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 448.6% Upside
$11.00 Price Target
Short Interest: Bearish
1.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.83
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$58,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.74) to ($2.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

683rd out of 986 stocks

Pharmaceutical Preparations Industry

331st out of 483 stocks

3.5

Analyst's Opinion

Consensus Rating
IO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, IO Biotech has a forecasted upside of 448.6% from its current price of $2.01.
Amount of Analyst Coverage
IO Biotech has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
1.71% of the float of IO Biotech has been sold short.
Short Interest Ratio / Days to Cover
IO Biotech has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
IO Biotech does not currently pay a dividend.
Dividend Growth
IO Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IOBT.

0.7

News and Social Media Coverage

News Sentiment
IO Biotech has a news sentiment score of -0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for IO Biotech this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IO Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $58,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.50% of the stock of IO Biotech is held by insiders.
Percentage Held by Institutions
53.23% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for IO Biotech are expected to grow in the coming year, from ($2.74) to ($2.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IO Biotech is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IO Biotech is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IO Biotech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IO Biotech (NASDAQ:IOBT) Stock

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Receive IOBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter.

IOBT Stock News Headlines

June 5, 2023 | americanbankingnews.com

Analyzing IO Biotech (IOBT) and The Competition

June 1, 2023 | finance.yahoo.com

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

June 6, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

May 25, 2023 | markets.businessinsider.com

Jefferies Reaffirms Their Buy Rating on IO Biotech (IOBT)

May 15, 2023 | americanbankingnews.com

IO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00

May 13, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on IO Biotech (IOBT)

May 11, 2023 | seekingalpha.com

IO Biotech GAAP EPS of -$0.59 beats by $0.09

May 11, 2023 | finance.yahoo.com

IO Biotech Announces 2023 First-Quarter Results

June 6, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

May 11, 2023 | americanbankingnews.com

IO Biotech (IOBT) vs. Its Competitors Head-To-Head Survey

May 2, 2023 | finance.yahoo.com

Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth?

March 25, 2023 | americanbankingnews.com

IO Biotech, Inc. (NASDAQ:IOBT) to Post Q1 2023 Earnings of ($0.68) Per Share, Jefferies Financial Group Forecasts

March 24, 2023 | americanbankingnews.com

IO Biotech, Inc. (NASDAQ:IOBT) Forecasted to Post Q4 2023 Earnings of ($0.68) Per Share

March 23, 2023 | americanbankingnews.com

Insider Buying: IO Biotech, Inc. (NASDAQ:IOBT) CFO Buys $58,000.00 in Stock

March 22, 2023 | finance.yahoo.com

The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares

March 17, 2023 | benzinga.com

IO Biotech Stock (NASDAQ:IOBT), Short Interest Report

March 14, 2023 | finance.yahoo.com

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

February 24, 2023 | barrons.com

IO Biotech Inc.

February 22, 2023 | finance.yahoo.com

IO Biotech to Participate in March 2023 Investor Conferences

January 24, 2023 | markets.businessinsider.com

Morgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)

January 23, 2023 | finance.yahoo.com

IO Biotech Announces Appointment of Devin Smith as General Counsel

January 9, 2023 | finance.yahoo.com

IO Biotech Provides Business Update

November 21, 2022 | finance.yahoo.com

Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'

November 9, 2022 | finance.yahoo.com

IO Biotech Announces Third Quarter Results for 2022

November 9, 2022 | finance.yahoo.com

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

November 3, 2022 | finance.yahoo.com

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

October 31, 2022 | finance.yahoo.com

IO Biotech to Participate in the Jefferies London Healthcare Conference

See More Headlines

IOBT Price History

30 days | 90 days | 365 days | Advanced Chart

IOBT Company Calendar

Last Earnings: 3/14/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IOBT
CUSIP: N/A
CIK: 1865494
Web: www.iobiotech.com
Phone: 45-7070-2980
Fax: N/A
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +447.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -48.61%
Return on Assets: -45.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.77
Quick Ratio: 12.77

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.82 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 28,815,000
Free Float: 27,806,000
Market Cap: $57.92 million
Optionable: Not Optionable
Beta: -0.69

Key Executives

Dr. Mai-Britt Zocca Ph.D. (Age 55)
Founder, Pres, CEO, Principal Financial Officer & Director
Comp: $514.12k

Dr. Muhammad Al-Hajj Ph.D. (Age 51)
Chief Scientific Officer
Comp: $486.63k

Dr. Eva Ehrnrooth M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $443.5k

Prof. Inge Marie Svane M.D.
Ph.D., Founder & Clinical Advisor

Prof. Mads Hald Andersen Ph.D.
Founder & Scientific Advisor

Anders Ljungqvist
Founder

Prof. Per Thor Straten
Founder

Ms. Amy B. Sullivan
Chief Financial Officer

Mr. Brian Burkavage (Age 39)
VP of Fin. & Chief Accounting Officer

Mr. Mikkel Dybkjær (Age 50)
VP of Corp. Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOBT Stock - Frequently Asked Questions

Should I buy or sell IO Biotech stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares.
View IOBT analyst ratings or view top-rated stocks.
What is IO Biotech's stock price forecast for 2023?: 2 equities research analysts have issued 12-month target prices for IO Biotech's shares. Their IOBT share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 447.3% from the stock's current price.
View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts.
How have IOBT shares performed in 2023?: IO Biotech's stock was trading at $2.30 at the beginning of 2023. Since then, IOBT stock has decreased by 12.6% and is now trading at $2.01.
View the best growth stocks for 2023 here.
When is IO Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IOBT earnings forecast.
How were IO Biotech's earnings last quarter?: IO Biotech, Inc. (NASDAQ:IOBT) announced its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.12.
When did IO Biotech IPO?: (IOBT) raised $111 million in an initial public offering on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share.

What is IO Biotech's stock symbol?: IO Biotech trades on the NASDAQ under the ticker symbol "IOBT."
Who are IO Biotech's major shareholders?: IO Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%).
View institutional ownership trends.
How do I buy shares of IO Biotech?: Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IO Biotech's stock price today?: One share of IOBT stock can currently be purchased for approximately $2.01.
How much money does IO Biotech make?: IO Biotech (NASDAQ:IOBT) has a market capitalization of $57.92 million. The company earns $-71,460,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.
How can I contact IO Biotech?: The official website for the company is www.iobiotech.com. The company can be reached via phone at 45-7070-2980.

This page (NASDAQ:IOBT) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial